期刊文献+

格列酮类(glitazones)口服胰岛素增敏剂的研究进展 被引量:3

暂未订购
导出
摘要 格列酮类药物是以噻唑烷二酮类化学结构为基础的一系列衍生物 ,是一类具口服活性的胰岛素增敏剂。研究显示其可高选择性地激动过氧化物酶增殖体活化受体 - γ(PPAR- γ) ,通过改善胰岛素抵抗 (insulin resistance,IR) ,不刺激胰岛素分泌 ,即可减少 IR的高血糖、高胰岛素血症及高甘油三酯。临床用于治疗 2型糖尿病。可见肝毒性。本文概要介绍曲格列酮 (troglitazone,Rezulia)、吡格列酮 (pioglitazone,Actos)和罗格列酮 (rosiglitazone,Avandia) 3种格列酮类药物的化学结构、药理作用、药代动力学及不良反应等的研究进展。
作者 李宝瑗
出处 《天津药学》 2002年第1期2-5,共4页 Tianjin Pharmacy
  • 相关文献

参考文献30

二级参考文献56

  • 1张卫.ACUPUNCTURE FOR TREATMENT OF DIABETIC URINARY BLADDER NEURAL DYSFUNCTION - A Report of 36 Cases[J].Journal of Traditional Chinese Medicine,1997,17(3):211-213. 被引量:1
  • 2征革凡,王金平,张辉,胡泽溪,刘娟,肖建中,陈仕明,曹辉碧,李光伟,胡英华,潘孝仁.拜糖平治疗非胰岛素依赖型糖尿病的临床观察[J].中华内分泌代谢杂志,1995,11(3):163-164. 被引量:43
  • 3[12]Yu Momose, Kanji Meguro, Hitoshi Ikena, et al. Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and relant compounds[J]. Chem Pharm Bull,1991,39(6): 1440-1445.
  • 4[13]Pioglitazone hydrochloride[J]. Drugs Fut, 1998,23 (11):1259-1260.
  • 5[14]Freie UB, Fachbereich Humanmedizin, Universitatsklinikum BF. Mechanismen und Klinische Wirksamkeit von Pioglitazon als neues Prinzip in der Behandlung des Typ-2-Diabetes[J]. Arzneim-Forsch/Drugs Res, 1999, 49 ( Ⅱ ): 835-842.
  • 6[15]Barrie CC, Michael AC, Graham PC, et al. [[w- (Heterocyclylamino ) alkoxy]benzyl] - 2,4 -thiazolidiones as potent antihyperglycemic agents[J]. J Med Chem, 1994, 37(23):3977-3985.
  • 7[16]Julia ABB, Greg LP. Rosiglitazone[J]. Drugs, 1999,57(6):921-930.
  • 8[17]Rosigiitazone Maleate[J]. Drugs Fut, 1998, 23 (9): 977-985.
  • 9[18]Braj BL, Vidya Bhushan, Bheema PR, et al. Novel euglycemic and hypolidemic Agents. 1 [J]. J Med Chem,1998, 41(10):1619-1630.
  • 10[19]Hemant KJ, Rao NVSM, Swaroopkurnar VSV, et al. Oral bioavailability and pharmacokinetics of the new insulin sensitizer DRF-2189 in wistar rats [J].Arzneim- Forsch/Drugs Res, 1999,49(Ⅰ): 133-136.

共引文献306

同被引文献31

  • 1李艳波,韩君勇,李为民.斯伐他汀对糖尿病肾病大鼠肾小球系膜细胞p38信号通路的影响[J].中华肾脏病杂志,2007,23(2):91-94. 被引量:10
  • 2甘淋,彭家和,鲁立,申丽丽,张迁,江渝.曲格列酮对THP-1巨噬细胞源性泡沫细胞ABCA 1表达及胆固醇流出的影响[J].现代生物医学进展,2007,7(1):82-84. 被引量:4
  • 3Oram JF, Lawn RM. ABCA1 : The gatekeeper for eliminatingexcess tissue cholesterol[J]. J Lipid Res,2001,42 (8) : 1173-1179.
  • 4Makita Z, Vlassara H, Ceramic A,et al. Immunochemical detection of advanced glycosylation end products in vivo [ J ]. J Boil Chem, 1992,267(8) : 5133-5138.
  • 5Oram JF. HLD apolipoprotein and ABCA1 partners in the removal of excess celluar cholesterol [ J ]. Arterrioscler Thromb vasc Biol, 2003,23(5 ) : 720-727.
  • 6Smith JD,Le Coff W,Settle M,et al. ABCA1 mediates concurrent cholesterol and phospholipids efflux to apolipoprotein A-1 [ J ]. J Lipid Res,2004,45 (4) : 635-644.
  • 7Oram JF,Lawn RM. ABCA1 :The gatekeeper for eliminating excess tissue cholesterol[ J ]. Lipid Res,2001,42 (8) : 1173-1179.
  • 8Li Ac, Binder C J, Gutierrez K, et al. Differential inhibitation of macrophage-derived foam cell formation and atherosclerosis in mice by PPARalpha, beta/data, and gamma [ J ]. J Clin Invest, 2004,114 ( 11 ) : 1564-1576.
  • 9Ricote M, Li AC, Willson TM, et al . The peroxisome proliferatoractivated receptor-gamma is a negative regulator of macrophage activation[J]. Nature,1998,391 (6662) : 79- 82.
  • 10Chawla A, Boisvert WA, Lee CH,et al. A PPAR-gamma-LXRAB- CA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis [ J]. Mol Cell,2001,7 ( 1 ) : 161-171.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部